The Texas Interprofessional Pharmacogenomics (IPGx)
The Texas Interprofessional Pharmacogenomics (IPGx) PILOT Cohort
Texas A&M University
50 participants
Dec 15, 2021
OBSERVATIONAL
Conditions
Summary
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.
Eligibility
Inclusion Criteria5
- People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs
- Ability to give and comprehend the consent process.
- Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination.
- All genders.
- Age 45 and over
Exclusion Criteria10
- Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.
- Admitted to hospice.
- Patient has ever been diagnosed with Hepatitis B or C.
- Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score >10, ALT or AST >100U/L or an AST/ALT ratio >2
- Patients taking imidazole antifungal medication.
- Declines to participate or interact with staff/share their medical status.
- A diagnosis of Alzheimer's disease
- Pregnant patients will be excluded
- Unable/unwilling to consent.
- Unable to verbally communicate and comprehend English/Spanish language.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06219720